Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on December 9, 2009, to report significant regulatory and commercial milestones regarding its lead product candidate, taliglucerase alfa, for the treatment of Gaucher's disease.
Key Financial Metrics
This filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed is a milestone payment triggered by the reported events.
- Milestone Payment: $5 million receivable from Pfizer Inc.
Material Changes and Events
The filing details the following material events occurring on December 9, 2009:
- Regulatory Submission: Completion of the New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for taliglucerase alfa.
- European Filing: Submission of a proposed pediatric investigation plan to the European Medicines Agency (EMEA) for a clinical study in patients aged 2 to 18.
- Commercial Agreement: The NDA submission triggers a $5 million milestone payment from Pfizer under the Exclusive License and Supply Agreement dated November 30, 2009.
Outlook and Management Commentary
Management announced plans to present the full Phase III trial results submitted in the NDA at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010, scheduled for February 10-12, 2010, in Miami, Florida. The filing does not contain specific forward-looking guidance on future revenue or operational targets beyond this presentation.
Investor Verification Checklist
- Confirm the receipt of the $5 million milestone payment from Pfizer and its impact on the company's cash position.
- Monitor the FDA's review timeline and decision on the taliglucerase alfa NDA.
- Review the full Phase III trial data presented at the February 2010 WORLD Symposium.
- Track the status of the pediatric investigation plan with the EMEA.